Cancer Immunotherapy Paradigms, Practice and Promise / edited by Tyler J. Curiel.

This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical tr...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Curiel, Tyler J. (Editor)
Format: eBook
Language:English
Published: New York, NY : Springer New York : Imprint: Springer, 2013.
Edition:1st ed. 2013.
Series:Springer eBook Collection.
Subjects:
Online Access:Click to view e-book
Holy Cross Note:Loaded electronically.
Electronic access restricted to members of the Holy Cross Community.

MARC

LEADER 00000nam a22000005i 4500
001 b3300177
003 MWH
005 20191028082230.0
007 cr nn 008mamaa
008 121116s2013 xxu| s |||| 0|eng d
020 |a 9781461447320 
024 7 |a 10.1007/978-1-4614-4732-0  |2 doi 
035 |a (DE-He213)978-1-4614-4732-0 
050 4 |a E-Book 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
245 1 0 |a Cancer Immunotherapy  |h [electronic resource] :  |b Paradigms, Practice and Promise /  |c edited by Tyler J. Curiel. 
250 |a 1st ed. 2013. 
264 1 |a New York, NY :  |b Springer New York :  |b Imprint: Springer,  |c 2013. 
300 |a X, 486 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a Springer eBook Collection 
505 0 |a Introduction -- Historical Perspectives and Current Trends in Cancer Immunotherapy -- T cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment -- Adoptive T Cell Transfer -- Dendritic Cell-Based Cancer Immunotherapy: Achievements and novel concepts -- Peptide and Protein-based Cancer Vaccines -- Antigen Targeting to Dendritic Cells for Cancer Immunotherapy -- Cytokines in the Treatment of Cancer -- Immune Co-signaling to Treat Cance -- Managing Regulatory T cells -- Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and therapeutic perspectives -- Antibodies as Cancer Immunotherapy -- Targeted Toxins in Cancer Immunotherapy -- Miscellaneous Approaches and Considerations: TLR agonists and other inflammatory agents, anti-chemokine agents, infectious agents, tumor stroma targeting, age and sex effects, and miscellaneous small molecules -- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies -- Monitoring Antigen-Specific Responses in Clinical Trials of Immunotherapy -- Index. 
520 |a This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies. Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy. Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press. 
590 |a Loaded electronically. 
590 |a Electronic access restricted to members of the Holy Cross Community. 
650 0 |a Cancer research. 
650 0 |a Pharmacology. 
690 |a Electronic resources (E-books) 
700 1 |a Curiel, Tyler J.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
830 0 |a Springer eBook Collection. 
856 4 0 |u https://holycross.idm.oclc.org/login?auth=cas&url=https://doi.org/10.1007/978-1-4614-4732-0  |3 Click to view e-book  |t 0 
907 |a .b33001777  |b 04-18-22  |c 02-26-20 
998 |a he  |b 02-26-20  |c m  |d @   |e -  |f eng  |g xxu  |h 0  |i 1 
912 |a ZDB-2-SBL 
950 |a Biomedical and Life Sciences (Springer-11642) 
902 |a springer purchased ebooks 
903 |a SEB-COLL 
945 |f  - -   |g 1  |h 0  |j  - -   |k  - -   |l he   |o -  |p $0.00  |q -  |r -  |s b   |t 38  |u 0  |v 0  |w 0  |x 0  |y .i22133392  |z 02-26-20 
999 f f |i 93f7e869-d4ef-513b-b5ce-ba105d78c9be  |s 473aeae8-7571-59a9-b671-083096c22fb6  |t 0 
952 f f |p Online  |a College of the Holy Cross  |b Main Campus  |c E-Resources  |d Online  |t 0  |e E-Book  |h Library of Congress classification  |i Elec File